Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to assess the efficacy of antiangiogenic therapy
(bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of
minimal systemic disease (based on rising PSA without metastases).
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Rutgers Cancer Institute of New Jersey